| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $101,621,240 ) (Continued on the next page) |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD109089 | Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial | 000 | 5 | NIH | 5/12/2026 | $686,430 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | U01AI165455 | Collective Responses to Malaria Vaccination | 000 | 5 | NIH | 1/20/2026 | $700,000 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI170777 | Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling | 000 | 4 | NIH | 5/19/2026 | $735,776 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01CA300296 | Menin and Ewing Sarcoma Metastasis | 000 | 1 | NIH | 3/30/2026 | $636,097 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K23AI193246 | Respiratory Syncytial virus specific immunity in hematopoietic cell transplant recipients | 000 | 2 | NIH | 8/20/2026 | $181,231 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD116794 | Randomized trial of a shared decision-making intervention for families about firearm storage | 000 | 2 | NIH | 6/19/2026 | $753,820 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | RM1DE035304 | Leveraging Advances in Practices and Outcomes in Cleft Care: The LEAP Study | 001 | 2 | NIH | 7/20/2026 | $1,222,744 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R00AI182458 | Elucidating a novel respiratory-mammary axis of T cell immunity | 000 | 3 | NIH | 4/2/2026 | $248,984 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HL183249 | Home Air Pollution in Children with Cystic Fibrosis (HEROIC-CF) | 000 | 1 | NIH | 5/5/2026 | $893,522 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI202709 | A prime-pull TB vaccine regimen optimized to induce lung-resident T cells | 000 | 1 | NIH | 7/30/2026 | $516,975 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R21OD042628 | Transgenesis in a novel mammalian model of adult regeneration | 000 | 1 | NIH | 7/28/2026 | $516,175 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI202709 | A prime-pull TB vaccine regimen optimized to induce lung-resident T cells | 000 | 1 | NIH | 7/30/2026 | $516,975 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI189738 | Impact of vaccination and preterm delivery on maternal RSV-specific peripheral and mucosal immunity | 000 | 1 | NIH | 2/20/2026 | $862,347 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | RF1AG062738 | Pericyte Structural Plasticity and Cerebrovascular Health in a Model of Type-1 Cerebral Amyloid Angiopathy | 000 | 6 | NIH | 6/19/2026 | $3,642,948 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI201425 | Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation | 000 | 1 | NIH | 8/4/2026 | $911,271 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01DK144249 | Selectively disrupting heterochromatin to improve function of hepatocytes reprogrammed from human fibroblasts | 000 | 1 | NIH | 5/5/2026 | $724,950 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD111410 | Development of a Multiplex Proteomics Assay for High-Throughput Newborn Screening of a New Set of Treatable Neonatal Diseases | 001 | 4 | NIH | 4/6/2026 | $63,126 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI177257 | Perturbations of host cell signaling by a complex hepatotropic pathogen | 000 | 14 | NIH | 1/14/2026 | $683,694 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD111410 | Development of a Multiplex Proteomics Assay for High-Throughput Newborn Screening of a New Set of Treatable Neonatal Diseases | 000 | 4 | NIH | 1/30/2026 | $568,132 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R00CA263161 | Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia | 000 | 5 | NIH | 3/30/2026 | $248,977 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K01DA058543 | Dissociating respiratory depression and analgesia via a data-driven model of interacting respiratory and pain networks | 000 | 4 | NIH | 3/19/2026 | $100,975 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | F32NS143860 | Brainstem control of apneic reflexes relating to respiratory deaths in neurological disorders | 000 | 2 | NIH | 8/7/2026 | $75,880 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI014102 | Mitochondrial DNA of Normal and Mutant Trypanosomes | 000 | 49 | NIH | 4/29/2026 | $1,158,683 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R37CA266777 | The IL-18-IFNγ axis predicts response to immunotherapy | 001 | 4 | NIH | 4/16/2026 | $79,347 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R37CA266777 | The IL-18-IFNγ axis predicts response to immunotherapy | 000 | 4 | NIH | 1/29/2026 | $714,132 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI185053 | Elucidating and targeting Siglec-9 function on mast cells | 000 | 2 | NIH | 6/18/2026 | $612,917 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | UH3OD035508 | Mediators and Modifiers of Prenatal Environmental Exposures and Child Neurodevelopment: DNA methylation, Prenatal Diet, and Cognitive Stimulation (MEND) | 000 | 4 | NIH | 7/8/2026 | $1,368,474 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01DE033703 | Leveraging Data for Infants with Cleft to Grow and Flourish: The BLOOM Study | 002 | 3 | NIH | 5/11/2026 | $786,044 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01MD015723 | The Family Bridge Program to Improve Communication and Navigation-Related Outcomes for Minority Children and Families: A Randomized Controlled Trial | 000 | 5 | NIH | 6/3/2026 | $771,245 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | T32GM156698 | Invent@SC Clinical Pharmacology of Biotherapeutics | 000 | 2 | NIH | 5/28/2026 | $357,586 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01NS143924 | Modeling mTOR network dynamics to achieve optimal drug rescue of congenital mTORopathies | 000 | 2 | NIH | 4/27/2026 | $704,697 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | U01DA060443 | Deep Analysis of Transcriptome to Understand the Genetics of Substance Use Disorders in Rats | 000 | 2 | NIH | 3/27/2026 | $882,279 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD116748 | Understanding Longitudinal Relationships between Sleep and Menstrual Pain in Adolescents | 000 | 2 | NIH | 5/22/2026 | $762,355 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI151167 | Manipulating alpha(v) integrins on B cells to promote lung-resident B cell responses | 000 | 5 | NIH | 3/27/2026 | $767,781 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AG081840 | Pericyte control of capillary perfusion in the Alzheimer's disease brain | 001 | 4 | NIH | 2/25/2026 | $84,440 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AG081840 | Pericyte control of capillary perfusion in the Alzheimer's disease brain | 000 | 4 | NIH | 2/2/2026 | $759,966 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HD106628 | Supraphysiologic Shear Stresses Associated with Cardiopulmonary Bypass are Sufficient to Activate RIKP3 Signaling | 000 | 5 | NIH | 3/3/2026 | $725,965 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01CA258866 | IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors | 001 | 5 | NIH | 2/19/2026 | $615,969 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI163160 | Dysregulated asthmatic epithelial interferon responses to viruses drive exacerbation, T2 inflammation, and airway remodeling | 000 | 5 | NIH | 1/22/2026 | $850,461 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R37NS095733 | Pathological Mechanisms of Human Cerebellar Malformations | 001 | 11 | NIH | 7/30/2026 | $967,274 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K08DK138302 | Epigenetic regulation of kidney regeneration | 000 | 3 | NIH | 5/28/2026 | $154,980 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | U01DK084575 | Continuation of the Childhood Liver Disease Research Network - Seattle Clinical Center | 001 | 18 | NIH | 6/12/2026 | $299,390 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K08CA277014 | Investigating SLC46A3 as a negative regulator of nanoparticle drug delivery | 000 | 4 | NIH | 7/14/2026 | $230,947 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HL163103 | Hexosamine biosynthesis pathway metabolism during cardiac hypertrophy | 001 | 4 | NIH | 4/24/2026 | $23,368 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01HL163103 | Hexosamine biosynthesis pathway metabolism during cardiac hypertrophy | 000 | 4 | NIH | 2/27/2026 | $740,074 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K08AI166072 | Dissecting the molecular regulation of T cell localization and function within the Mycobacterium tuberculosis granuloma | 000 | 5 | NIH | 1/28/2026 | $183,968 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI158536 | Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | 001 | 5 | NIH | 4/2/2026 | $87,480 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | R01AI158536 | Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | 000 | 5 | NIH | 3/20/2026 | $623,601 |
| | 2026 | 2026 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3901 | KING | USA | K22AG081323 | The Role of Hematopoietic Loss of Y Chromosome on Aging Phenotypes | 000 | 3 | NIH | 8/17/2026 | $186,408 |
|
